bioRxivSystems BiologyPreprint
Reversible Opto-Chemical activation of KRASG12V signaling with near single-cell precision
Luis Manuel Muñoz-NavaiD, Maria BespalovaiD, Mario O. CaracciiD, Kitso Ata KewagamangiD, Birga SoetjeiD, Sabrina SeidleriD, Kirsten MicheliD, Holger Vogel, Janicke Maerz, Philippe I. H. BastiaensiD
Abstract
KRAS mutations drive some of the most lethal carcinomas, and genomic and inducible systems have established many of the cellular and tissue-level consequences. However, these approaches operate at the level of oncogene expression, allowing for cellular adaptation that masks the individual role of KRAS oncoprotein signaling. Here, we developed a reversible Opto-Chemical system to activate KRAS signaling by chemically translocating a cytosolic mutant KRASG12V G-domain to the plasma membrane upon light or small-molecule input. In MDCK cells, the G-domain plasma membrane recruitment activated downstream signaling and reduced collective migration. In mouse small Intestinal Organoids, G-domain recruitment promoted increased crypt size and number under Epidermal Growth Factor-deprived conditions. We further showed that the increased number of crypts depended on continuous KRASG12V signaling. Finally, under the same deprived conditions, localized activation in just one budding crypt promoted crypt formation compared to controls. This system decouples oncoprotein activity from oncogene expression, allowing to investigate the KRAS signaling contribution to early epithelial transformation.
- organism: mouse
- research focus: drug response / drug discovery
- research focus: perturbation response prediction
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells
N. L. Hindul, L. R. Abbott, … K. Tanaka·bioRxiv·Sep 8, 2023
- Development of a new flippase-dependent mouse model for red fluorescence-based isolation of KrasG12D oncogene-expressing tumor cells
Dušan Hrčkulák, Jakub Onhajzer, … Vladimír Kořínek·Transgenic ResearchPeer-reviewed·Jan 9, 2025
- Signaling by RasG12V depends on EGFR activity in vivo
Patricia Vega-Cuesta, Ana López‐Varea, … José Félix de Celis·bioRxiv·Nov 12, 2025
- Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium
- VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation
Sung‐Hyun Hwang, Mingyun Bae, … Keun‐Wook Lee·bioRxiv·Sep 16, 2025
- Oncogene-Mechanics Axis: KRAS G12C Confers Agility Enabling Malignant Mechano-responses to Peristalsis in Colorectal Cancer
Astha Lamichhane, Vsevolod D. Cheburkanov, … Shreya Artha Raghavan·Scientific ReportsPeer-reviewed·Sep 1, 2026